Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chunbao Zang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Fangfang Zhao

    Department of Cancer Epigenetics Program, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China

    5 shared publications
  • Hongxiao Lin

    Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    3 shared publications
  • Lingsuo Kong

    Department of Anesthesiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, People’s Republic of China

    3 shared publications
  • Ying Dai

    Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    3 shared publications
  • Youguang Pu

    Department of Cancer Epigenetics Program, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China

    3 shared publications
  • Youguang Pu

    Department of Cancer Epigenetics Program, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230031, China

    3 shared publications

Latest Publications

  • Open Access

    YY1-induced upregulation of DLGAP5 promotes tumor progression in lung adenocarcinoma via Wnt/β-catenin/EMT pathway

    by Jiahe Li, Hong Kuang, Jiayu Lu, Xiaokang Shen, Qiang Lu, Chunbao Zang

    DLGAP5 is frequently upregulated in human cancers and is associated with tumor progression. However, its biological role, regulatory mechanism, and downstream signaling in lung adenocarcinoma (LUAD) remain unclear. Public databases were used to analyze DLGAP5 expression, diagnostic value, and prognostic significance across cancers, especially in LUAD. Functional assays in LUAD cells and xenograft models were performed to evaluate the effects of DLGAP5 on proliferation, migration, invasion, and tumor growth. Mechanistic studies were conducted to examine cell cycle- and EMT-related proteins, as well as the transcriptional regulation of DLGAP5 by YY1. DLGAP5 was significantly upregulated in multiple cancers and showed strong diagnostic value. High DLGAP5 expression predicted poor overall survival and disease-specific survival, and was an independent prognostic factor in LUAD. DLGAP5 knockdown inhibited LUAD cell proliferation, migration, invasion, and tumor growth. Mechanistically, DLGAP5 silencing reduced CDK4 and CDK6 expression and suppressed the Wnt/β-catenin/EMT pathway, as shown by decreased N-cadherin, Slug, Snail, Twist1, and β-catenin, with increased E-cadherin. In addition, YY1 directly bound to the DLGAP5 promoter and positively regulated its expression. YY1 knockdown reduced DLGAP5 expression and impaired LUAD progression. DLGAP5 promotes LUAD progression by enhancing cell proliferation, metastasis, and EMT, while YY1 acts as its upstream transcriptional activator. The YY1/DLGAP5 axis may serve as a potential prognostic biomarker and therapeutic target in LUAD.

  • Open Access

    LAMTOR5-AS1 Regulates Chemotherapy-induced Oxidative Stress via the miR-34a-3p/SIRT1/HNF4A Axis in Osteosarcoma Cells

    by Fangfang Zhao, Chao Wei, Youguang Pu, Chunbao Zang

    Introduction: Osteosarcoma (OS) drug resistance often leads to a poor prognosis. Recent evidence suggests that long non-coding RNAs play a crucial role in regulating tumor drug resistance. Methods: This study aims to investigate the involvement of lncRNA LAMTOR5-AS1 in OS. RNA-seq and qRT-PCR were performed, and the relationship between LAMTOR5- AS1, miR-34a-3p, SIRT1, and HNF4A was determined using Dual-luciferase reporter assays and RNA immunoprecipitation assays. Gain- and loss-of-function assays were measured using CCK-8, cell proliferation, and colony formation assays. Results: The study found that the dysregulated LAMTOR5-AS1 acts as a competing endogenous RNA (ceRNA) and competitively protects the HNF4A mRNA 3’ UTR from miR-34a-3p. In addition, in vitro functional studies showed that HNF4A can physically interact with SIRT1 to synergistically inhibit osteosarcoma drug resistance. The study found that LAMTOR5-AS1 regulates drug resistance in osteosarcoma through the miR-34a-3p/HNF4A or miR-34a-3p/SIRT1/HNF4A axis. Conclusion: These findings offer new insights into lncRNA-mediated drug resistance in cancer and may serve as potential biomarkers for cancer therapy.


  • Open Access

    Primary cutaneous mucinous carcinoma of the cheek: a case report

    by Ying Dai, Yufei Zhang, Hongxiao Lin, Chunbao Zang

    Primary cutaneous mucinous carcinoma is a rare neoplasia of the sweat gland. The age-adjusted incidence was 0.024 tumors per 100,000 person-years. It is possible that the actual number of tumors may be slightly higher than previously estimated as some cases of primary cutaneous mucinous carcinoma may have been mistaken for benign tumors and removed by laser therapy without histologic examination. We report a 58-year-old Chinese man with primary cutaneous mucinous carcinoma. The patient presented to our care with an indolent nodule on the left cheek, which was proven to be a mucinous adenocarcinoma by excisional biopsy and immunohistochemical staining. Following a comprehensive evaluation, including whole-body computed tomography and positron emission tomography, metastases from other sites were ruled out and the patient was diagnosed with primary cutaneous mucinous carcinoma. The patient underwent an additional wide resection surgery to ensure a safe margin and was then recommended to undergo regular follow-up. This case is one of the few published Chinese cases in literature of primary cutaneous mucinous carcinoma. Diagnosis of primary cutaneous mucinous carcinoma is challenging, and treatment options are limited. Collaboration between clinicians and pathologists is crucial for optimal outcomes. Further studies with longer follow-up periods are necessary to provide evidence for the management of this disease.

  • Open Access

    The antagonistic effect of FTO on METTL14 promotes AKT3 m6A demethylation and the progression of esophageal cancer

    by Ran Wei, Fangfang Zhao, Lingsuo Kong, Youguang Pu, Yuanhai Li, Chunbao Zang

    Background: As the most abundant modification in eukaryotic messenger RNAs (mRNAs), N6-methyladenosine (m6A) plays vital roles in many biological processes. Methods: Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptomic RNA sequencing (RNA-seq) were used to screen for m6A targets in esophageal cancer cells and patients. The role of m6A RNA methylase in esophageal cancer was also analyzed using bioinformatics. In vitro and in vivo experiments were used to analyze gene expression and function. CCK-8, colony formation, cell apoptosis and immunofluorescence staining assays were performed to evaluate the proliferation, migration and invasion of esophageal cancer cells, respectively. Western blot analysis, RNA stability, RIP and luciferase reporter assays were performed to elucidate the underlying mechanism involved. Results: We found that the m6A demethylase FTO was significantly upregulated in esophageal cancer cell lines and patient tissues. In vivo and in vitro assays demonstrated that FTO was involved in the proliferation and apoptosis of esophageal cancer cells. Moreover, we found that the m6A methyltransferase METTL14 negatively regulates FTO function in esophageal cancer progression. FTO alone is not related to the prognosis of esophageal cancer, and its function is antagonized by METTL14. By using transcriptome-wide m6A-seq and RNA-seq assays, we revealed that AKT3 is a downstream target of FTO and acts in concert to regulate the tumorigenesis and metastasis of esophageal cancer. Taken together, these findings provide insight into m6A-mediated tumorigenesis in esophageal cancer and could lead to the design of new therapeutic strategies.


  • Open Access

    Dosimetry of intensity-modulated radiation therapy and volumetric-modulated arc therapy techniques after modified radical mastectomy for breast cancer and hypofractionated intensity-modulated radiotherapy

    by Hongxiao Lin, Xuren Sheng, Haowu Liu, Peng Zhang, Yunqin Liu, Chunbao Zang

    Objective: The aim of this study was to compare the advantages and disadvantages of intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with left-sided breast cancer who underwent hypofractionated IMRT after a modified radical mastectomy. Materials and Methods: Twenty patients who required adjuvant radiotherapy after modified radical mastectomy were randomly selected, and a specified dose of 43.5 Gy/15 F was used to plan for IMRT or VMAT. Dose–volume histograms (DVHs) were utilized to evaluate the dose distribution of the planning target volumes (PTVs) and organs at risk (OARs). Results: VMAT demonstrated a greater and more uniform dose distribution of PTVs and lower number of monitor units. No significant differences were found in V 5 of the affected lung and heart between the two techniques ( P > 0.05). The V 10 , V 20 , V 30 , and D mean of the affected lung and V 10 , V 20 , V 30 , V 40 , D mean , and D max of the whole heart were better in the VMAT than in the IMRT ( P < 0.05). The D mean and D max of the left anterior descending (LAD) branch of the coronary artery of the heart were better in the VMAT ( P < 0.05), and the use of the VMAT effectively reduced the cardiopulmonary dose. A significant advantage of V 30 and D mean was also found in VMAT ( P < 0.05). Conclusion: These findings indicate that VMAT has higher clinical significance than IMRT, because it improved the dose distribution in the target area, reduced the cardiopulmonary dose, protected the OARs (e.g. thyroid), and shortened the treatment duration.


  • Open Access

    Cutaneous metastasis from cervical cancer to the scalp and trunk: a case report and review of the literature

    by Ying Dai, Yufei Zhang, Xue Ke, Yunqin Liu, Chunbao Zang

    Background: An estimated 119,300 new cases of cervical cancer occur annually in China, accounting for 372,00 deaths. Cutaneous metastasis from cervical cancer is a rare event, with an incidence of 0.1–1.3% and typically a preterminal occurrence. Scalp metastasis from cervical cancer is exceptionally anecdotal, with only a dozen examples well documented. Case presentation: The patient is a 33-year-old Chinese woman who was diagnosed with International Federation of Gynecology and Obstetrics stage IVB cervical cancer in November 2021. From December 2021 to April 2022, the patient was enrolled in the clinical trial of sintilimab combined with chemotherapy and radiotherapy for treatment of stage IV cervical cancer and underwent six cycles of immunotherapy and chemotherapy (sintilimab plus paclitaxel liposome and cisplatin). Treatment was well tolerated and led to a partial response. The masses adjacent to the spine and iliac bone was largely reduced. Thus, radiotherapy of the metastatic residues was carried out and followed by radiotherapy to the primary tumor at the cervix uteri. However, by the time of the radiotherapy completion in October 2022, the patient noticed painless nodules at the left scapular region and the right hypochondrium. The following month, more nodules occurred on the scalp and trunk, including the left axilla, anterior abdomen, and left back, along with a lesion invading the sternum that caused acute bone pain. The cutaneous masses were white, discrete with a rubbery consistency, and fixed to the skin. Several nodules increased in size and eventually ulcerated. Fine‑needle aspiration cytology of the left back swellings revealed metastatic squamous cell carcinoma, P16 positive. No visceral or brain metastasis was observed at this point. Conclusions: Cervical cancer metastases to the scalp are extremely uncommon. When a scalp metastasis is present, it might be the only symptomatic sign of disease progression or widespread metastatic lesions. So far, there is no clear guideline regarding skin metastases treatment. Such skin lesions warrant a thorough radiologic and pathologic workup to form a comprehensive management plan.


  • Open Access

    Profiling the m6A-regulated RNA expression patterns and alternative splicing features in esophageal carcinoma

    by Lingsuo Kong, Fei Gao, Fangfang Zhao, Ran Xia, Cifeng Cai, Weixin Wang, Dabing Huang, Zhenyu Li, Qiyi Yi, Chunbao Zang, et al.


  • Open Access

    Comparative Dosimetric Study of Intensity-modulated Radiotherapy and Volumetric-modulated Arc Therapy Techniques with Hypofractionated Intensity-modulated Radiotherapy after Modified Radical Mastectomy for Breast Cancer

    by Hongxiao Lin, Xuren Sheng, Haowu Liu, Peng Zhang, Li Yin, Chengsheng Xu, Xue Ke, Jin Ni, Ke Liu, Yachao Yin, et al.

    Background This study aimed to compare the advantages and disadvantages of intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), in left-sided breast cancer patients who underwent hypofractionated intensity-modulated radiotherapy after a modified radical mastectomy. Methods For the study, 20 patients with left-sided breast cancer who required adjuvant radiotherapy after a modified radical mastectomy were selected randomly. The specified dose of 43.5Gy/15f was adopted to plan for the IMRT and the VMAT. Dose volume histograms (DVH) were employed to evaluate the dose distribution of planning target volumes and organs at risk in both plans. Results The homogeneous index (HI) and conformity index (CI) of the VMAT group were found to be better than those of the IMRT group (P < 0.05). VMAT showed better and more uniform dose distribution in the planning target volumes as well as a lower monitor unit (MU).No significant difference was found in V5 of the affected lung and heart between the two groups (P > 0.05). V10, V20, V30, and Dmean of the affected lung and whole heart V10, V20, V30, V40, Dmean, and Dmax of the VMAT group were better than those of the IMRT group (P < 0.05). Dmean and Dmax of the left anterior descending (LAD) of the heart in the VMAT group were better than those in the IMRT group (P < 0.05), and the VMAT program was effective in reducing cardiopulmonary dose. A significant advantage of V30 and Dmean was found in the VMAT group over the IMRT group (P < 0.05). Conclusions Compared with the IMRT program, the VMAT program achieved a higher clinical value since it improved the dose distribution in the target area, reduced the cardiopulmonary dose, protected organs at risk (OAR) (e.g., the thyroid), and shortened the treatment time.

  • Open Access

    The m6A demethylase FTO promotes esophageal cancer progression via the YTHDF1/AKT3 signaling network

    by Chunbao Zang, Ran Wei, Fangfang Zhao, Zhenyu Li, Lingsuo Kong, Yuanhai Li

    As the most abundant modification in eukaryotic messenger RNAs (mRNAs), the N6-methyladenosine (m6A) plays vital roles in many biological processes. Here we applied the methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptomic RNA sequencing (RNA-seq) to screen the m6A targets in esophageal cancer patients. We found that the m6A demethylase FTO was significantly up regulated in esophageal cancer cell lines and patient tissues. In vivo and in vitro assays demonstrated that FTO was involved in the proliferation, migration, invasion, and apoptosis of esophageal cancer cells. Moreover, we found that the m6A methyltransferase METTL14 negatively regulates FTO function on esophageal cancer progression. By using transcriptome-wide m6A-seq and RNA-seq assays, we identified that AKT3 is a downstream target of FTO, which acts in concert to regulate the tumorigenesis and metastasis of esophageal cancer. All these findings revealed insights into the m6A-regulated tumorigenesis in esophageal cancer, which is applicable for designing new therapeutic strategy.